Warfarin therapeutic response predictive Assay VKORC1 and CYP2C9 Test
At DNA Labs UAE, we offer the Warfarin therapeutic response predictive Assay VKORC1 and CYP2C9 Test. This genetic test analyzes two genes, VKORC1 and CYP2C9, to predict an individual’s response to the anticoagulant drug warfarin.
Test Details
The Warfarin therapeutic response predictive assay is a genetic test that analyzes the VKORC1 and CYP2C9 genes. These genes play a crucial role in determining an individual’s response to warfarin, a commonly used anticoagulant drug.
Warfarin is used to prevent blood clots, but the optimal dose varies among individuals. Too high of a dose can increase the risk of bleeding, while too low of a dose may not effectively prevent clotting. Genetic variations in the VKORC1 and CYP2C9 genes can affect how an individual metabolizes warfarin and how sensitive they are to its effects.
The VKORC1 gene provides instructions for producing the vitamin K epoxide reductase enzyme, which warfarin inhibits. Variations in this gene can affect the amount of enzyme produced, and therefore, how much warfarin is needed to achieve the desired anticoagulant effect.
The CYP2C9 gene provides instructions for producing the CYP2C9 enzyme, which is responsible for metabolizing warfarin in the liver. Variations in this gene can affect the enzyme’s activity, leading to differences in warfarin metabolism and clearance from the body.
By analyzing the genetic variations in VKORC1 and CYP2C9, the Warfarin therapeutic response predictive assay can provide information on an individual’s likely response to warfarin treatment. This information can help healthcare providers determine the optimal dose of warfarin for each patient, reducing the risk of adverse effects and improving treatment outcomes.
Test Components
- EDTA Vacutainer (2ml)
Test Price
The cost of the Warfarin therapeutic response predictive Assay VKORC1 and CYP2C9 Test is 1280.0 AED.
Sample Condition
The test requires a peripheral blood sample.
Report Delivery
The test results will be delivered within 3-4 days.
Method
The test is performed using the End Point PCR + RFLP method.
Test Type
The Warfarin therapeutic response predictive Assay VKORC1 and CYP2C9 Test falls under the category of Genetics tests.
Doctor
The test is recommended by oncologists.
Test Department
The Warfarin therapeutic response predictive Assay VKORC1 and CYP2C9 Test is conducted in the DNA Labs UAE’s Test Department.
Pre Test Information
Please note that the Warfarin therapeutic response predictive Assay (VKORC1 & CYP2C9) requires a doctor’s prescription. However, the prescription is not applicable for surgery and pregnancy cases or individuals planning to travel abroad.
| Test Name | Warfarin therapeutic response predictive Assay VKORC1 and CYP2C9 Test |
|---|---|
| Components | EDTA Vacutainer (2ml) |
| Price | 1280.0 AED |
| Sample Condition | Peripheral blood |
| Report Delivery | 3-4 days |
| Method | End Point PCR + RFLP |
| Test type | Genetics |
| Doctor | Oncology |
| Test Department: | |
| Pre Test Information | Warfarin therapeutic response predictive Assay (VKORC1 & CYP2C9) can be done with a Doctors prescription. Prescription is not applicable for surgery and pregnancy cases or people planing to travel abroad. |
| Test Details | The Warfarin therapeutic response predictive assay is a genetic test that analyzes two genes, VKORC1 and CYP2C9, to predict an individual’s response to the anticoagulant drug warfarin. Warfarin is commonly used to prevent blood clots, but the optimal dose varies among individuals. Too high of a dose can increase the risk of bleeding, while too low of a dose may not effectively prevent clotting. Genetic variations in the VKORC1 and CYP2C9 genes can affect how an individual metabolizes warfarin and how sensitive they are to its effects. The VKORC1 gene provides instructions for producing the vitamin K epoxide reductase enzyme, which warfarin inhibits. Variations in this gene can affect the amount of enzyme produced, and therefore, how much warfarin is needed to achieve the desired anticoagulant effect. The CYP2C9 gene provides instructions for producing the CYP2C9 enzyme, which is responsible for metabolizing warfarin in the liver. Variations in this gene can affect the enzyme’s activity, leading to differences in warfarin metabolism and clearance from the body. By analyzing the genetic variations in VKORC1 and CYP2C9, the Warfarin therapeutic response predictive assay can provide information on an individual’s likely response to warfarin treatment. This information can help healthcare providers determine the optimal dose of warfarin for each patient, reducing the risk of adverse effects and improving treatment outcomes. |
